EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 335 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... April 24, 2019 Robin Williams Required Film Companies He Worked With To Hire Homeless... November 25, 2021 Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... February 12, 2024 Teacher on Leave for Breast Cancer Treatment Forced to Pay for... May 8, 2019 Load more HOT NEWS Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... Merging the Histologic and Molecular Data Into an Integrated Score Significantly... FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma Mother and Son with Shared BRCA Gene Mutation Go Through Cancer...
